Modern etiotropic therapy of chronic viral hepatitis B

Chronic viral hepatitis B (CHB) is a significant global health problem. The biological characteristics of the hepatitis B virus, which causes this disease, significantly impede the achievement of complete virus elimination in most patients. In this regard, the rational choice of drugs and antiviral...

Full description

Saved in:
Bibliographic Details
Main Authors: E. B. Bun'kova, N. A. Bileva, A. E. Bilev, M. I. Sinel'nikov
Format: Article
Language:Russian
Published: Private institution educational organization of higher education "Medical University "ReaViz" 2024-10-01
Series:Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье
Subjects:
Online Access:https://vestnik.reaviz.ru/jour/article/view/1028
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849402788341088256
author E. B. Bun'kova
N. A. Bileva
A. E. Bilev
M. I. Sinel'nikov
author_facet E. B. Bun'kova
N. A. Bileva
A. E. Bilev
M. I. Sinel'nikov
author_sort E. B. Bun'kova
collection DOAJ
description Chronic viral hepatitis B (CHB) is a significant global health problem. The biological characteristics of the hepatitis B virus, which causes this disease, significantly impede the achievement of complete virus elimination in most patients. In this regard, the rational choice of drugs and antiviral therapy regimens is crucial for increasing life expectancy and improving the quality of life in patients with CHB. The purpose of this literature review is to identify current approaches and trends in etiotropic therapy for CHB.Materials and methods. The review uses data published in domestic and foreign scientific journals, clinical guidelines, regulatory documents, and Internet resources.Results. Currently, the most effective means of etiotropic therapy for CHB are interferons (standard interferon alpha, pegylated interferons alpha-2a and alpha-2b), as well as first-line nucleoside/nucleotide analogs (entecavir, tenofovir) and second-line analogs (lamivudine, telbivudine, adefovir). The choice of a specific drug is determined by the patient's clinical condition, preferences, availability, and cost of treatment. Despite certain limitations of current etiotropic therapies for CHB, their use can significantly increase patients' life expectancy and improve their quality of life.
format Article
id doaj-art-41b7348e26db4570a7ec4ef923dff776
institution Kabale University
issn 2226-762X
2782-1579
language Russian
publishDate 2024-10-01
publisher Private institution educational organization of higher education "Medical University "ReaViz"
record_format Article
series Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье
spelling doaj-art-41b7348e26db4570a7ec4ef923dff7762025-08-20T03:37:28ZrusPrivate institution educational organization of higher education "Medical University "ReaViz"Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье2226-762X2782-15792024-10-01144768610.20340/vmi-rvz.2024.4.CLIN.4650Modern etiotropic therapy of chronic viral hepatitis BE. B. Bun'kova0N. A. Bileva1A. E. Bilev2M. I. Sinel'nikov3Reaviz Medical UniversityReaviz Medical UniversityReaviz Medical UniversitySamara Regional Children's Infectious Diseases HospitalChronic viral hepatitis B (CHB) is a significant global health problem. The biological characteristics of the hepatitis B virus, which causes this disease, significantly impede the achievement of complete virus elimination in most patients. In this regard, the rational choice of drugs and antiviral therapy regimens is crucial for increasing life expectancy and improving the quality of life in patients with CHB. The purpose of this literature review is to identify current approaches and trends in etiotropic therapy for CHB.Materials and methods. The review uses data published in domestic and foreign scientific journals, clinical guidelines, regulatory documents, and Internet resources.Results. Currently, the most effective means of etiotropic therapy for CHB are interferons (standard interferon alpha, pegylated interferons alpha-2a and alpha-2b), as well as first-line nucleoside/nucleotide analogs (entecavir, tenofovir) and second-line analogs (lamivudine, telbivudine, adefovir). The choice of a specific drug is determined by the patient's clinical condition, preferences, availability, and cost of treatment. Despite certain limitations of current etiotropic therapies for CHB, their use can significantly increase patients' life expectancy and improve their quality of life.https://vestnik.reaviz.ru/jour/article/view/1028chronic viral hepatitis bhepatitis b virusinterferonsnucleoside/nucleotide analogsetiotropic therapyantiviral therapy
spellingShingle E. B. Bun'kova
N. A. Bileva
A. E. Bilev
M. I. Sinel'nikov
Modern etiotropic therapy of chronic viral hepatitis B
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье
chronic viral hepatitis b
hepatitis b virus
interferons
nucleoside/nucleotide analogs
etiotropic therapy
antiviral therapy
title Modern etiotropic therapy of chronic viral hepatitis B
title_full Modern etiotropic therapy of chronic viral hepatitis B
title_fullStr Modern etiotropic therapy of chronic viral hepatitis B
title_full_unstemmed Modern etiotropic therapy of chronic viral hepatitis B
title_short Modern etiotropic therapy of chronic viral hepatitis B
title_sort modern etiotropic therapy of chronic viral hepatitis b
topic chronic viral hepatitis b
hepatitis b virus
interferons
nucleoside/nucleotide analogs
etiotropic therapy
antiviral therapy
url https://vestnik.reaviz.ru/jour/article/view/1028
work_keys_str_mv AT ebbunkova modernetiotropictherapyofchronicviralhepatitisb
AT nabileva modernetiotropictherapyofchronicviralhepatitisb
AT aebilev modernetiotropictherapyofchronicviralhepatitisb
AT misinelnikov modernetiotropictherapyofchronicviralhepatitisb